본문으로 가기

학술대회 발표자료

제13회 대한다발성경화증학회 심포지움

일시: 2017-08-19 장소: 서울 쉐라톤 신도림 디큐브시티호텔 6층 그랜드볼룸
  • 1. Multiple sclerosis (MS)

    석흥열(계명의대)
  • 2. Neuromyelitis optica (NMO)

    이혜림(고려의대)
  • 3. Neurogenic bladder: Botox treatmen

    이규성(성균관의대, 비뇨기과)
  • 4. Overview: MOA of new drugs

    조중양(인제의대)
  • 5. Oral drug

    박민수(영남의대)
  • 6. Natalizumab

    신현준(국립암센터)
  • 7. Alemtuzumab

    임영민(울산의대)
  • 8. Principle-based approach: Academic view

    민주홍(성균관의대)
  • 9. Real-practice-based approach: Coverage of NHI

    오지영(건국의대)
  • 10. Kim, S.-H., J.-W. Hyun, et al. (2017). "Predictors of response to first-line immunosuppressive therapy in neuromyelitis optica spectrum disorders." Mult Scler: 1352458516687403.

    김수현(국립암센터)
  • 11. Seok, J. M., H.-J. Cho, et al. (2017). "Clinical characteristics of late-onset neuromyelitis optica spectrum disorder: A multicenter retrospective study in Korea." Mult Scler: 1352458516685416

    석진명(순천향의대)
  • 12. Kim, S.-M., et al. (2016). "Gender effect on neuromyelitis optica spectrum disorder with aquaporin4-immunoglobulin G." Mult Scler: 1352458516674366.

    김성민(서울의대)
  • 13. Jeong IH, Kim HJ, Kim NH, Jeong KS, Park CY (2016) Subclinical primary retinal pathology in neuromyelitis optica spectrum disorder J Neurol 2016 Jul;263(7):1343-8.

    김남희(동국의대)